Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics

Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities. Diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Trang, M., Lakota, E. A., Safir, M. C., Bhavnani, S. M., Friedrich, L., Steenbergen, J. N., McGovern, P. C., Tzanis, E., Rubino, C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112242/
https://www.ncbi.nlm.nih.gov/pubmed/36916956
http://dx.doi.org/10.1128/aac.02397-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112242/
https://www.ncbi.nlm.nih.gov/pubmed/36916956
http://dx.doi.org/10.1128/aac.02397-21

Ejemplares similares